Ibuprofen, a common over-the-counter pain reliever, has shown promise in alleviating cognitive issues associated with chemotherapy, according to a recent study. This research, led by Professor Michelle Janelsins from the University of Rochester Medicine, suggests that a low dose of ibuprofen can be a valuable tool in managing the cognitive challenges faced by cancer patients during and after treatment.
The study, published in the journal Cancer, involved 86 cancer patients undergoing chemotherapy who reported cognitive problems. Participants were randomly assigned to one of four groups: a combination of a proprietary exercise program called EXCAP©® and ibuprofen, EXCAP©® alone, ibuprofen alone, or a placebo. The results were striking, indicating that both exercise and ibuprofen, either individually or together, could significantly reduce cognitive fog.
What makes this study particularly intriguing is its focus on patient-reported outcomes and the involvement of family and friends in assessing cognitive improvements. By including these subjective observations, the research highlights the real-world impact of these interventions on daily life.
Professor Janelsins emphasizes the importance of exercise, noting that it appeared to be more beneficial than ibuprofen alone. She states, 'Having patients do as much as they can is better than nothing.' This finding underscores the potential of exercise as a powerful tool in combating chemo-brain, a term used to describe cognitive difficulties such as memory lapses, attention issues, and multitasking challenges.
The study's design also sets it apart by addressing chemo-brain specifically and incorporating objective cognitive tests alongside patient-reported data. This comprehensive approach allows for a more nuanced understanding of the interventions' effectiveness.
While ibuprofen showed some positive effects, the study suggests that exercise may be more consistently effective in improving cognitive functions. However, it is crucial for patients to consult their oncology team before incorporating any new interventions to ensure safety and avoid potential drug interactions.
Looking ahead, Professor Janelsins and her team plan to expand their research, including larger nationwide trials and exploring higher doses and longer durations of ibuprofen. This ongoing work aims to further solidify the role of exercise and low-dose ibuprofen in supporting cancer patients' cognitive health during and beyond their treatment journey.
